Introduction
Prostate cancer has a diverse range of findings and it can present as a small indolent intraprostatic lesion to highly aggressive disseminated disease. Biological heterogeneity presents a diagnostic challenge and it is important to understand the underlying mechanism of spread of prostate cancer. A reporting radiologist or nuclear medicine physician should be aware of varying appearances of prostate at different stages and the spectrum of findings with different biomarkers utilizing PET-CT or PET-MRI. We validated our findings on the PET-CT appearances of prostate cancer presenting as focal or diffuse uptake [1] [2] [3] . This article relates to the phenotypic appearances of the prostate with a range of biomarkers that facilitate the diagnosis of prostate cancer and these can be categorized into different groups:
(1) Increased choline kinase activity ( 18 F-methylcholine, 18 F-ethylcholine and 11 C-choline). (2) Prostate-specific membrane proteins ( 68 Ga-PSMA). 
Biomarkers Radiolabelled choline
There is an increased proliferation of cells in cancer with increased choline kinase activity. This enzyme is important for phosphorylation and choline uptake is increased as a result of this. There are three radiolabelled subtypes of choline ( 18 F-methylcholine, 18 F-ethylcholine and 11 C-choline). Normal biodistribution of these three subtypes of radiolabelled choline has been described by Haroon et al. [4] . Visceral localization of radiolabelled choline is the same for all subtypes. There are only minor differences that fall in the category of statistically significant or nonsignificant differences. The range of standardized uptake values for various organs for the three tracers was also evaluated in this study. The main utility of radiolabelled choline PET is in the detection of biochemical relapse of prostate cancer [2] . 68 Ga-PSMA Prostate-specific membrane antigen (PSMA) is present in prostate epithelial cells, salivary glands, renal tubular cells, the small intestine and coeliac ganglia. Three properties of PSMA make it a highly attractive target for imaging: (a) increased expression in prostate cancer cells, (b) cell membrane anchorage and (c) internalization. 68 Ga-PSMA is more sensitive and specific than radiolabelled choline in patients with recurrent prostate cancer [5] .
F-FDG

2-[
18 F]-fluoro-2-deoxy-D-glucose ( 18 F-FDG) is a radiolabelled analogue of glucose and it also uses transmembrane glucose transporters to enter a cell that is phosphorylated by hexokinase. As 18 F-FDG shows low uptake in newly diagnosed prostate cancer, it is of only limited value for local staging of prostate cancer. 68 
Ga-DOTATATE
Somatostatin is a cyclic neuropeptide and it is found in neurons and endocrine cells. There are five subtypes of somatostatin receptors (SSTRs) that may frequently coexist in the same cell. There is overexpression of SSTR in prostate cancer and 30% of prostate cancer cells [6] express SSTR. 68-Gallium 1,4,7,10-tetraazacyclododecane-1,4,7, 10-tet-raaceticacid(DOTA)-octreotate ( 68 Ga-DOTATATE, GaTate) PET-CT allows cell surface expression of SSTRs.
Differential diagnosis Malakoplakia
Malacoplakia is derived from the Greek words 'malakos' meaning 'soft' and 'plakos', meaning 'plaque', and the first person to coin this term was Von Hansemann. Malacoplakia is a chronic inflammatory condition with different aetiologies including tuberculosis, tumours, fungal infections, parasitic infestations, sarcoidosis, ectopic rests of adrenal cortical cells and coliform infections. Histological hallmarks are Von Hansemann cells and Michaelis-Gutmann bodies. Clinically, the genitourinary tract is the most common site, with 80-90% of patients having coliform infection.
Case study
A 71-year-old man of Caribbean origin presented with proximal muscle weakness and sensory loss in all four limbs. His erythrocyte sedimentation rate was 100. His treponemal antibody enzyme-linked immunosorbent assay was positive (syphilis), rapid plasma reagin was positive at a titre of 4 and Treponema pallidum particle agglutination assay was also positive. Sural nerve biopsy was in keeping with segmental demyelination with axonal degeneration. A diagnosis of chronic inflammatory demyelinating neuropathy was made.
18 F-FDG PET-CT (Fig. 1) showed a nonavid lung lesion. There was a single focus of 18 F-FDG uptake at the right lateral aspect of the prostate and, on biopsy, malakoplakia was confirmed.
Rhabdomyosarcoma
Prostatic sarcomas are rare and arise from the mesoderm and constitute 0.7% of the primary tumours of the prostate [7] . There is an increased risk of local recurrence in patients with genitourinary sarcomas compared with sarcomas of the soft tissues [8, 9] . In the paediatric population, rhabdomyosarcoma with localized and metastatic disease have a better prognosis [10] . American Joint Committee on Cancer has recategorized nodal involvement from stage IV to stage III because of better prognosis [10] . MRI with superior anatomical resolution and PET providing additional information on the nodal and distant status of disease can help in triaging patients for surgery.
Case study
An 18-month-old boy presented with urinary outflow obstruction and bilateral hydronephrosis. MRI and 18 F-FDG PET-CT scan ( Fig. 2 ) indicated a soft tissue mass bulging into the bladder, displacing it anteriorly, and was adherent to the rectum. Histology showed embryonic rhabdomyosarcoma with anaplasia localized to the bladder neck and prostate. He was treated with chemotherapy and follow-up PET-CT scan showed residual low-grade uptake in the primary mass lesion with no evidence of metabolically active metastatic disease.
Lymphoma
These are low-grade malignancies and the incidence is the highest in the seventh decade [3, 4, 11, 12] . The following features raise the possibility of primary lymphoma of the prostate [11] :
(1) Symptoms related to prostatic enlargement. ( 2) The predominant site of involvement is the prostate. (3) Absence of involvement of the liver, spleen and lymph nodes (1 month of diagnosis). 18 F-FDG PET-CT provide additional information as it is possible to differentiate these from diffuse large B-cell lymphoma [13] on histology.
(1) High-grade adenocarcinoma shows nuclear pleomorphism and cellular cohesion with large sheets of tumour cells. However, infiltrative adenocarcinoma are more difficult to distinguish. Most of the adenocarcinomas are negative for CD45, CD20, whereas diffuse large B-cell lymphoma shows positivity with this immunoprofile [12] . (2) Urothelial carcinomas show cellular cohesion including solid tumour nests and no invasive carcinoma on the surface urothelium. There exists an overlap with diffuse large B-cell lymphoma with extreme morphological diversity, invasive, discohesive tumour cells. Urothelial carcinomas are positive for pancytokeratin, CK903/34BE12, p63 and GATA3. These are negative for CD45 and CD20.
(3) Small cell carcinoma show sheet-like growth, small blue cells with scant cytoplasm, a high nuclear to cytoplasmic ratio, salt and pepper chromatin, nuclear moulding, single cell or geographic necrosis. Small cell carcinomas express pancytokeratin, chromogranin and synaptophysin. These lack CD45 and CD20.
Prostate cancer Acinar adenocarcinoma
Adenocarcinomas (Figs 3 and 4) are the most common type of prostate cancer. It develops in the gland cells that line the prostate [14] . Ductal adenocarcinoma starts in the cells that line the ducts (tubes) of the prostate gland. It tends to grow and spread more quickly than acinar adenocarcinoma. When the uptake pattern of 18 F-ethylcholine PET-CT was correlated with MR template-guided mapping biopsies, it was found that 60 min imaging was more sensitive than 90 min imaging for the detection of clinically significant prostate cancer [2] .
Transitional cell (or urothelial) cancer
Transitional cell cancer of the prostate starts in the cells that line the tube carrying urine to the outside of the body (the urethra). There is more than 50% 5-year disease-specific survival rate for patients with transitional cell carcinoma of the prostate [15] and it was found that the extent of locoregional spread was the strongest rate predictor of patient survival outcome.
Squamous cell cancer
These cancers develop from flat cells that cover the prostate. They tend to grow and spread more quickly than adenocarcinoma of the prostate. These are extremely rare, comprising only 0.5-1% of all prostatic carcinomas [16] .
Small cell prostate cancer
Small cell prostate cancer is made up of small round cells. It is a type of neuroendocrine cancer [14] . These are rare and can be mistaken for high-grade conventional prostate carcinoma. It has a poor prognosis.
Neuroendocrine tumours of the prostate
Primary neuroendocrine carcinomas are divided into two main types:
(1) High-grade histological type (small cell carcinoma). (2) Low-grade histological type (carcinoid tumours) [17] .
Prostate carcinoid are associated with adenocarcinomas [18] , transdifferentiation from adenocarcinomas [19] and multiple endocrine neoplasia [20] . These lesions pose a diagnostic challenge because of several overlapping features such as adenocarcinomas, and may show neuroendocrine features (carcinoid-like growth pattern) and positive immunostaining for neuroendocrine markers [21] . It is of crucial importance to know whether the cancer is conventional adenocarcinoma with neuroendocrine differentiation or a true neuroendocrine carcinoma. PET/MRI and PET/CT of prostate Haroon et al. 199 In a study by Shastry et al. [22] , the distribution pattern of 68 Ga-DOTATATE in disease-free patients was evaluated and the uptake was found to be low grade and diffuse in the prostate. There is a low density of sst2 receptors in the normal prostate gland in the smooth muscles.
Case study
A male patient with calcified mass in the tail of the pancreas with intense SSTR expression was diagnosed with a pancreatic neuroendocrine tumour on histology. There were multiple tracer-avid metastatic deposits in the liver (Fig. 5) and also periportal lymph nodes. The images of the pelvis showed heterogeneous tracer uptake in the central gland of the prostate.
Uchida changes
High-frequency focused ultrasound utilizes the physical properties of ultrasound. When it is used for therapy, it can be focused by an acoustic lens, a transducer or an electronic phased array. This creates zones of high and low pressure through the tissues, and this causes thermal coagulation and/or acoustic cavitation [23] . On a PET-CT scan, it is difficult to identify changes on the low-dose CT as the focal point is small (10 mm × 1-2 mm) and is situated along the long axis of the beam. These changes are called 'Uchida changes' [24] and were described by Professor Toyoaki Uchida in Japan. There are three grades: grade I, changes identified within the treatment zones; grade II, confluent between the adjacent treatment zones and grade III, migration outside the treatment zone. The changes are further subclassified into three types on the basis of the involvement of the focal regions: (a) <10%, (b) 10-50% and (c) > 50%. The overall impact of treatment results in altered morphology of the gland, which are very difficult to recognize on the lowdose PET-CT with formation of subsequent scar tissue. If MRI is available, then anatomical alteration, particularly 'Uchida changes', should be evaluated. Cavitation, fistulation (Fig. 6 ) and asymmetrical atrophic changes should be considered before labelling a tracer-avid disease site as a tumour. Excreted activity because of focal small cavitation adjacent to the urethra may accumulate urinary activity and can be misdiagnosed as a metabolically active pathological lesion.
Postradiotherapy
The main utility of PET is the detection of early biochemical relapse. Novel biomarkers have the potential to differentiate viable disease versus postsurgical and postradiotherapy changes [25] . In the postradiotherapy scenario, there is a relatively poor yield of 18 F-FDG and choline, with prostate-specific antigen less than 4 ng/ml [26] . The most common reason for false-positive result is postradiotherapy-related inflammatory change.
Case study
A 72-year-old man with a history of prostate cancer presented with biochemical relapse (prostate-specific antigen 12.67). The patient underwent 18 F-choline PET-CT, which Increasing prostate-specific antigen was noted in a patient with a previous history of prostate cancer, left seminal vesicle involvement, which was removed at surgery and then treated with radiotherapy. 68 Ga-PSMA PET-CT showed a focal area of uptake at the poster aspect of the bladder on the left side with soft tissue abnormality on the low-dose CT. This is in keeping with disease relapse.
showed a moderate-intensity focal uptake in the right lobe of the prostate gland and no evidence of tracer-avid disease in the contralateral lobe. The patient underwent MR template-guided biopsy of the prostate, which showed only fibrosis on the right side and Gleason 3 + 4 adenocarcinoma of the prostate on the left side. The scan was false positive in the right lobe and false negative in the left lobe.
Posthormones
Hormones suppress the choline uptake of prostate cancer. There are limited studies that have evaluated this effect. It is recommended that androgen deprivation therapy should be put on hold before choline PET-CT to avoid a false-negative outcome [27] . This is of utmost importance in the clinical scenario of biochemical relapse of prostate cancer in hormone-naive patients.
Post-transurethral resection of the prostate
Transurethral resection of the prostate causes an increase in the diameter of the prostatic urethra. The prostatic urethra appears capacious with focal intense uptake when delayed imaging with 18 F-FDG or when radiolabelled choline is used. The intensity of uptake matches that of the excreted activity in the urinary bladder.
Postprostatectomy
Radical prostatectomy is the removal of the entire prostate gland. The modern methods encourage the use of nerve-sparing surgery to preserve the erectile function. Prostatectomy involves partial or complete removal of the prostate. PET-CT readers should be aware of two surgical approaches as postoperative scarring will alter the morphology of the prostate bed and perineum. Functional imaging helps to distinguish scar tissue from tumour recurrence or metastases (Fig. 7) .
Rectoprostatic fistula
Rectoprostatic fistula are either because of inflammatory aetiologies (abscess formation, xanthogranulomatous prostatitis), iatrogenic (postsurgical, brachytherapy, highfrequency focused ultrasound) or related to primary prostate cancer [28] .
Case study
A patient presented with left-sided hydronephrosis and hydroureter. Investigations indicated left vesicoureteric junction obstruction. MRI showed a large prostate cancer with infiltration of the left lateral aspect of the pelvis and fistula formation with the rectum. 18 F-choline PET-CT showed a heterogenous appearing mass with photopenic areas (Fig. 8) . A right lower lobe lung nodule was observed and it was intensely avid on 18 F-FDG PET-CT. On original histology, it was believed to be because of small cell carcinoma of the lung. On PSMA staining, the diagnosis of metastases from prostate cancer was confirmed. This patient showed significant progression on bone scan, with the development of osteoblastic bone metastases within an interval of 6 months.
Synchronous malignancies Prostate and skin cancer
There is a 1% incidence of skin metastases in patients with prostate cancer [29] and it is noteworthy that there is an increased risk of melanoma after prostate cancer treatment [29] . At our institute, a patient who was being investigated for suspected relapse of the prostate cancer had 18 F-choline PET-CT, which showed relapse at the mid-gland and the left lobe. An intensely avid nodule was noted at the left shoulder, which was clinically considered to be skin metastases from prostate cancer. The biopsy was confirmed to be squamous cell carcinoma of the skin (Fig. 9) . PET/MRI and PET/CT of prostate Haroon et al. 201 Prostate and rectal carcinoma
We came across a patient who had 18 F-choline PET-CT as part of a work-up for prostate cancer relapse. There was a focal area of intense uptake in the rectum at the left lateral wall. On retrospective review of the MRI, it was found to be a nodular lesion situated at the lateral wall of the rectum. It was difficult to detect it initially on a zoomed narrow field of view images, but on direct inspection, it was found to be a rectal carcinoma detected incidentally on MRI and 18 F-choline PET-CT.
Schwanoma
Benign tumours originating from the neuronal sheath are known as neurilemmomas or schwanomas. These occur along the distribution of the cranial nerves and in the flexor surfaces of the upper and lower extremeties. Most of these are incidentally detected as part of staging. 18 F-choline axial fused PET-CT images in a patient after radical prostatectomy. There is a speculated mildly avid soft tissue abnormality in the left ischiorectal fossa, which was a metastatic deposit from prostate cancer. Focal intense uptake at the left inguinal region is excreted activity in the drainage tube of the urinary catheter. 
Lymphocoele
These are collections of fluid secondary to disruption and surgical dissection of the lymphatics and lymph nodes. These are not metabolically active unless there is an inflammatory reaction. Low-dose CT detects these as hypodense area with well-defined margins.
Conclusion
It is concluded that there exists a wide differential for prostatic and periprostatic pathologies. As a nuclear medicine physician, it is important to be aware of the range of prostatic and periprostatic pathologies. Biological heterogeneity presents a diagnostic challenge in the detection of prostate cancer. Choline uptake in the cells can be because of inflammation, prostatic hyperplasia and malignancy. PSMA is present in prostate epithelial cells, renal tubular cells and coeliac ganglia. Overall, 30% of prostate cancer shows overexpression of SSTRs. Malacoplakia can be because of tuberculosis, sarcoidosis, tumours and fungal infections. When reporting PET for the evaluation of prostate cancer, the reporting nuclear medicine physician should evaluate the morphology of the prostate gland, particularly in cases where previous treatment has been administered, check the pelvis and other nodal stations for involvement and assess for the presence of incidental findings. (Fig. 10 , Supplemental Digital Content 1, http://links.lww.com/NMC/A126
68 Ga PSMA PET-CT with bilateral lung metastases). 
